There were no new or excess cases of the special interest AEs of myelodysplastic syndrome or acute myeloid leukemia, pneumonitis, and new primary malignancies in the olaparib arm, nor any AEs leading to death since the initial report, the presenter added.

There were no grade 5 TEAEs in either study arm and no cases of myelodysplastic syndrome or acute myeloid leukemia.

Among the 26% who did not recover there were eight cases of secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and a further 15% of patients died, including two deaths from disease progression, two from AML, and individual cases of sepsis, hemorrhage, and multiorgan failure.

The triplet and doublet regimens “had manageable safety profiles,” and were not associated with an increased risk for myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or other secondary malignancies relative to paclitaxel alone, said Loibl.

And none of the AEs of special interest – including pneumonitis, myelodysplastic syndrome or acute myeloid leukemia – “occurred at a higher frequency in the olaparib group than in the placebo group,” write the study authors, but they stress the need for longer follow-up.

The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.

And there were no cases of myelodysplastic syndromes or acute myeloid leukemia.

Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.

However, this positive opinion does not include use in patients with chronic myeloid leukemia or myelodysplastic syndromes. --- The Committee adopted a negative opinion for marketing authorization for the hybrid medicine Cabazitaxel Teva (Teva Europe BV, Amsterdam, the Netherlands), alongside prednisone or prednisolone, in patients with metastatic castration-resistant prostate cancer, who have previously been treated with docetaxel.

By contrast, medically intense interventions were less likely in patients with a diagnosis of acute myeloid leukemia or myelodysplastic syndrome versus acute lymphoblastic leukemia, those who received HSCT during 2000–2004 versus 2010–2013, those who changed hospitals between HSCT and death, and patients receiving care in a rural versus an urban location.

A reduced-intensity conditioning regimen offers at least equivalent 2-year relapse-free and overall survival to a myeloablative conditioning regimen before allogeneic transplantation in patients with myelodysplastic syndrome, RICMAC researchers report.

Mutations in the TP53 gene are the strongest independent predictor of reduced survival after allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome, results of a genetic profiling study show.

“Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease,” explain the researchers who examined the relationship between different classes of systemic agents and the risk for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

By contrast, cancers categorized as “other myelodysplastic syndromes” had decreased 5-year relative survival, falling from 34% in 1999–2001 to 30% in 2005–2007.

Adult patients with acute myeloid leukemia or myelodysplastic syndromes who have an unfavorable-risk cytogenetic profile or harbor TP53 mutations could benefit from treatment with decitabine, indicate findings.

Five patients given niraparib developed myelodysplastic syndrome, whereas there was one case of myelodysplastic syndrome and a second of acute myeloid leukaemia among the placebo-treated patients.